MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer. - Wikidata - awgldk - TriplyDB

MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer.

MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer.

http://www.wikidata.org/entity/Q34089034

about

The emerging role of miR-506 in cancer MicroRNA-Based Linkage between Aging and Cancer: from Epigenetics View Point Key nodes of a microRNA network associated with the integrated mesenchymal subtype of high-grade serous ovarian cancer Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers miR-506: a regulator of chemo-sensitivity through suppression of the RAD51-homologous recombination axis The role of microRNAs in ovarian cancer MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer MiR-506 is down-regulated in clear cell renal cell carcinoma and inhibits cell growth and metastasis via targeting FLOT1 MicroRNA-506 suppresses growth and metastasis of oral squamous cell carcinoma via targeting GATA6.MicroRNA-93 promotes ovarian granulosa cells proliferation through targeting CDKN1A in polycystic ovarian syndrome.MiR-506 suppresses tumor proliferation and invasion by targeting FOXQ1 in nasopharyngeal carcinoma microRNA-506 regulates proliferation, migration and invasion in hepatocellular carcinoma by targeting F-spondin 1 (SPON1)MicroRNA-506 suppresses tumor proliferation and metastasis in colon cancer by directly targeting the oncogene EZH2 Research Progress of MicroRNA in Early Detection of Ovarian Cancer Plasma miRNA-506 as a Prognostic Biomarker for Esophageal Squamous Cell Carcinoma MicroRNA-506 is up-regulated in the development of pancreatic ductal adenocarcinoma and is associated with attenuated disease progression.Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB signaling.Current status on microRNAs as biomarkers for ovarian cancer.MicroRNA-124 upregulation inhibits proliferation and invasion of osteosarcoma cells by targeting sphingosine kinase 1.MiR-24-3p enhances cell growth in hepatocellular carcinoma by targeting metallothionein 1M.MicroRNA-506 inhibits esophageal cancer cell proliferation via targeting CREB1.MicroRNA-137 inhibits cell migration and invasion by targeting bone morphogenetic protein-7 (BMP7) in non-small cell lung cancer cells miR-539 induces cell cycle arrest in nasopharyngeal carcinoma by targeting cyclin-dependent kinase 4.MicroRNA-506 inhibits gastric cancer proliferation and invasion by directly targeting Yap1.Differential expression of PDGFRB and EGFR in microvascular proliferation in glioblastoma.MIIP haploinsufficiency induces chromosomal instability and promotes tumour progression in colorectal cancer.MicroRNAs in gynecological cancers: Small molecules with big implications.Overexpression of miR-506 suppresses proliferation and promotes apoptosis of osteosarcoma cells by targeting astrocyte elevated gene-1 Overexpression of miR-506 inhibits growth of osteosarcoma through Snail2.The miR-506-Induced Epithelial-Mesenchymal Transition is Involved in Poor Prognosis for Patients with Gastric Cancer.miR-506 suppresses neuroblastoma metastasis by targeting ROCK1 ADAMTS16 mutations sensitize ovarian cancer cells to platinum-based chemotherapy.MIR506 induces autophagy-related cell death in pancreatic cancer cells by targeting the STAT3 pathway.MicroRNA expression profiles in non‑epithelial ovarian tumors.CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer.MiR-613 induces cell cycle arrest by targeting CDK4 in non-small cell lung cancer.Cellular Senescence in the Treatment of Ovarian Cancer.Long noncoding RNA gastric cancer-related lncRNA1 mediates gastric malignancy through miRNA-885-3p and cyclin-dependent kinase 4.miR-506 attenuates methylation of lncRNA to inhibit migration and invasion of breast cancer cell lines via targeting SP1 and SP3 MicroRNA-506 suppresses invasiveness and metastasis of human hepatocellular carcinoma cells by targeting

P2860

Q26740283-ECA55956-ECD5-4FC5-8AC5-A9E017033EAE Q26740297-582E4E04-A547-4588-BDB4-E2B6718F880E Q28082679-96A521FD-7444-4A01-A548-B56DE0511ACC Q28262260-36809745-5D9F-4EE8-B30D-B8AF1C131AFE Q28267333-0C84783D-742F-4C83-AF27-CD15721CE76A Q34253436-C0EF2A59-C4F7-416E-965F-E11D9B41680A Q34718013-7DE902A6-E203-45BF-960C-EF13F62C0FBE Q35202716-9618C02F-4156-4F9B-8413-FBCC78DE0C32 Q35479487-EF57D2C5-24C5-4E1D-9CD2-52E3DBF27EF0 Q35578288-392E6D12-990C-4D03-A9B7-A105D52D79D4 Q35598357-2AA4250B-EDB7-4F0E-9A13-6BE922152DC2 Q36250621-F1653C1E-F382-4F64-BB4B-11D220021C53 Q36544911-8B194FDD-F987-4AF6-BB7E-9A650DE5BE52 Q36701651-CACAD949-28B8-40EA-ADCB-97C29B60BB20 Q37052433-33B2CA77-733A-4E5D-8744-5933EBE9B08D Q37059641-B85AD1D3-E05E-4B9E-8780-BA501F925506 Q37364111-2E4A5DC6-A597-426A-8B77-696B68BEF67F Q38711390-F9BAB8EA-0C8C-4CDD-99ED-46978237003A Q38741167-381858E9-2C52-4A6E-BD8D-16F8C06525A9 Q38744683-EAB1DE35-74FD-4A7A-BA61-AB2CE315562F Q38815837-CC376D33-B7E7-412D-91FC-58C94CEA5C40 Q38815845-5A631EE5-B4AB-4A6C-98CB-11729A458579 Q38820169-046C510C-050F-424A-9771-F1259E18830B Q38890422-F29B0BC4-6CC8-4623-8340-0311DAA4FF5C Q38910687-C7DFE217-AE16-46F5-A32A-2B98B7414A1F Q39291148-877EE790-C538-4C96-9B02-EFEEAAA08744 Q39333266-18B5D1FE-6210-4E5C-BC5C-81FE0DB0A973 Q39415400-87686FEA-789B-42C5-9C0A-1F9BE6E63127 Q39991427-C1C0962E-3CB9-4303-ABB7-32552D8040B9 Q41365132-279DBAE4-8799-4A23-84A5-ABAA9D5AD667 Q42329734-D0F3C1B1-750B-4365-A308-E798FB7B7328 Q47135713-FF53CBD3-A0FC-4747-90E2-ACCD76CB20D7 Q48857817-D4EC0CF9-6233-4F35-B2C9-843F0CBE84CE Q50014321-047E71E4-B954-4E26-9CE6-6360829EF315 Q52592862-3E6C0B70-C79A-404E-9586-5125641AABC4 Q52890100-F11C8477-0444-4E94-B5F5-21B05704C3E0 Q53692066-411FDB06-607E-424A-8F22-6488E99C4E80 Q54978485-9293EE1B-10C7-45F0-97DE-6AC654186B4A Q58553627-D277BBAA-4615-41BA-8224-363CC7D53460 Q58804590-FE2C0B4C-CF9C-472E-85F5-A05CCAF0FBCE

P2860

MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer.

http://www.wikidata.org/entity/Q34089034

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

MiR-506 suppresses proliferati ...... -FOXM1 axis in ovarian cancer.

@ast

MiR-506 suppresses proliferati ...... -FOXM1 axis in ovarian cancer.

@en

MiR-506 suppresses proliferati ...... -FOXM1 axis in ovarian cancer.

@nl

type

label

MiR-506 suppresses proliferati ...... -FOXM1 axis in ovarian cancer.

@ast

MiR-506 suppresses proliferati ...... -FOXM1 axis in ovarian cancer.

@en

MiR-506 suppresses proliferati ...... -FOXM1 axis in ovarian cancer.

@nl

prefLabel

MiR-506 suppresses proliferati ...... -FOXM1 axis in ovarian cancer.

@ast

MiR-506 suppresses proliferati ...... -FOXM1 axis in ovarian cancer.

@en

MiR-506 suppresses proliferati ...... -FOXM1 axis in ovarian cancer.

@nl

P1433

Q34089034-9B3A74A5-DA4B-41F9-86B1-765138AF0FA1

P1476

Q34089034-0A132FA4-2426-4AC5-A503-0D99F88830C3

P2093

Q34089034-3F93F449-5EB9-4D80-A058-D07BCB62F371

Q34089034-83318973-FD74-4182-A559-6A4FFDF51A49

Q34089034-8622C5AA-26A9-443E-9394-22E0ADD07F0C

Q34089034-941C1FCC-9D80-4F94-9A50-0E9E2996DBB6

Q34089034-9AA855CF-AE91-4C78-B145-AFF100D7A5E5

Q34089034-B0935931-64E8-4910-9965-0CAF26F87D41

Q34089034-B3E320FD-4F1A-44E4-B2B4-B11FBD6C42BB

Q34089034-B50D5ED4-9417-4A29-9962-D8FAB902928A

Q34089034-CFF184C5-F8CC-42A4-8FA1-F7FC355811A8

Q34089034-E145A111-71A1-44AC-AD2F-F7576EA67971

P2860

Q34089034-095EA0D0-8FFA-4FCE-921E-409C475B10B7

Q34089034-0D8DA6FE-175A-4A18-A182-05A726535152

Q34089034-0DCA08B9-37F2-4C9A-90E7-81FBC0B8ED2E

Q34089034-13DA7B15-E8F4-4282-8B3D-C4626E0D0B1F

Q34089034-190FA3FF-6BDE-407D-B16B-8B778E8763CE

Q34089034-1B8610C7-00FE-4FCB-9ED5-E88B73391CC3

Q34089034-2B2802B3-C53E-4650-9F79-605C5FB5C5E7

Q34089034-2C8E8B19-6E9F-4D30-83A3-F0034AE07D79

Q34089034-2CDB6B9B-1F2D-4F7F-B003-C2043200CA54

Q34089034-2F57F8DC-EE26-4876-B3CE-D66A7709A065

P304

Q34089034-B46C1B51-3461-4079-804A-3F9BFAE095AB

P31

Q34089034-79B44745-3C6C-4614-9503-DB629FB954C1

P356

Q34089034-5E9D1349-9562-46BC-90DD-6B0B11494E24

P433

Q34089034-C0BF14C5-97C4-41A5-A8A2-DCF95BBB8DFC

P478

Q34089034-1F5A0F60-B7C3-489E-9AA8-79B4B7411B43

P50

Q34089034-E4742906-2D69-4427-8155-74AE603E388E

P577

Q34089034-BB1CAAF0-194C-4631-BBF6-88E088D99434

P5875

Q34089034-42264E9E-1A32-442C-ACFD-37D82E209410

P698

Q34089034-9AB3A53E-0229-481C-A879-BD6CFAA07FF4

P921

Q34089034-E5811510-F5C6-4589-8459-2055A0F7AC9F

P932

Q34089034-72ECC7EC-425A-41A6-8A70-DDFFD3D0DB94

P356

P1433

The Journal of Pathology

P1476

MiR-506 suppresses proliferati ...... -FOXM1 axis in ovarian cancer.

@en

P2093

Anil K Sood

http://www.w3.org/2001/XMLSchema#string

Brittany C Parker Kerrigan

http://www.w3.org/2001/XMLSchema#string

Da Yang

http://www.w3.org/2001/XMLSchema#string

David Cogdell

http://www.w3.org/2001/XMLSchema#string

Fengxia Xue

http://www.w3.org/2001/XMLSchema#string

Guoyan Liu

http://www.w3.org/2001/XMLSchema#string

Kexin Chen

http://www.w3.org/2001/XMLSchema#string

Ping Ji

http://www.w3.org/2001/XMLSchema#string

Wei Zhang

http://www.w3.org/2001/XMLSchema#string

Xia Li

http://www.w3.org/2001/XMLSchema#string

P2860

A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells

CDK4 and CDK6 delay senescence by kinase-dependent and p16INK4a-independent mechanisms

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

Integrated genomic analyses of ovarian carcinoma

Cancer statistics, 2013

Cyclin-dependent kinase pathways as targets for cancer treatment

Requirement for CDK4 kinase function in breast cancer

Cellular senescence: when bad things happen to good cells

Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data.

P304

308-318

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PATH.4348

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

233

http://www.w3.org/2001/XMLSchema#string

P50

Ilya Shmulevich

P577

2014-05-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260606521

http://www.w3.org/2001/XMLSchema#string

P698

24604117

http://www.w3.org/2001/XMLSchema#string

P921

P932

4144705

http://www.w3.org/2001/XMLSchema#string